albumin conjugate is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-31. Numbers and descriptions here follow the published literature rather than marketing material.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
== External links == NetSurfP ver. 1.1 – Protein Surface Accessibility and Secondary Structure Predictions α-helix rotational angle calculator Archived 2021-08-03 at the Wayback Machine Artist Julie Newdoll's website Artist Julian Voss-Andreae's website
=== Immigration === In February 2026, Talarico said he supported the Dignity Act, a proposed bipartisan immigration reform bill. In a January 2026 debate, he called for the increase in funding for ICE during the Trump administration to be diverted to other services. Talarico has described himself as a "border security Democrat" and criticized former President Joe Biden's border policy, saying it "created chaos in our border communities".
== Properties == Polymer-Protein nanoparticles not only contain the traditional properties of nanoparticles, but also have their own unique properties based on the properties of specific proteins. Because they are proteinaceous, they have high biocompatibility, biodegradability and biofunctionality. Protein-polymer bioconjugates which is the building block of Polymer-Protein hybrids exhibit a unique array of properties such as: light-switching effects, acoustic signal capture, thermal energy transfer, and magnetic signal response.
== Function == The protein encoded by this gene is a serum protein that binds insulin-like growth factors, increasing their half-life and their vascular localization. Production of the encoded protein, which contains twenty leucine-rich repeats, is stimulated by growth hormone. Three transcript variants encoding two different isoforms have been found for this gene.
6-Hydroxynicotinate 3-monooxygenase (EC 1.14.13.114, NicC, 6HNA monooxygenase, HNA-3-monooxygenase) is an enzyme with systematic name 6-hydroxynicotinate,NADH:oxygen oxidoreductase (3-hydroxylating, decarboxylating). This enzyme catalyses the following chemical reaction
Sources: en.wikipedia.org
According to the American Heart Association (AHA) a chest x-ray should not be used to diagnose or assess for aortic dissections. The AHA states that chest x-rays are not adequately sensitive nor specific to accurately diagnose aortic dissections. However, certain findings on a chest x-ray may suggest an aortic dissection. These findings include: widening of the mediastinum, disruption of the normal contour of the aortic knob, the calcium sign (a separation of more than 5 mm of the calcified intimal plaque layer from the aortic wall), a "double density" seen in the aorta, and deviation of the trachea to the right.
== Epidemiology == The exact number of cases of rhabdomyolysis is difficult to establish because different definitions have been used. In 1995, hospitals in the U.S. reported 26,000 cases of rhabdomyolysis. Up to 85% of people with major traumatic injuries will experience some degree of rhabdomyolysis. Of those with rhabdomyolysis, 10–50% develop acute kidney injury. The risk is higher in people with a history of illicit drug use, alcohol misuse, or trauma when compared to muscle diseases, and it is particularly high if multiple contributing factors occur together. Rhabdomyolysis accounts for 7–10% of all cases of acute kidney injury in the U.S. Crush injuries are common in major disasters, especially in earthquakes. The aftermath of the 1988 Spitak earthquake prompted the establishment, in 1995, of the Renal Disaster Relief Task Force, a working group of the International Society of Nephrology (a worldwide body of kidney experts). Its volunteer doctors and nurses assisted for the first time in the 1999 İzmit earthquake in Turkey, where 17,480 people died, 5392 were hospitalized, and 477 received dialysis, with positive results. Treatment units are generally established outside the immediate disaster area, as aftershocks could potentially injure or kill staff and make equipment unusable. Acute exertional rhabdomyolysis happens in 2% to 40% of people going through basic training for the United States military. In 2012, the United States military reported 402 cases. Another group at increased risk is firefighters.
== External links == NPR2+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH) This article incorporates text from the United States National Library of Medicine, which is in the public domain.
=== Water purification === Graphite oxides were studied for desalination of water using reverse osmosis beginning in the 1960s. In 2011, additional results from research were published. In 2013, Lockheed Martin announced their Perforene graphene filter. Lockheed claims the filter reduces energy costs for reverse osmosis desalination by 99%. Lockheed claimed that the filter was 500 times thinner than the best filter on the market, 1,000 times stronger, and required 1% of the pressure. The product was not expected to be released until 2020. Another study showed that graphite oxide could be engineered to allow water to pass while retaining some larger ions. Narrow capillaries allow rapid permeation by mono- or bilayer water. Multilayer laminates have a structure similar to nacre, which provides mechanical strength in water-free conditions. Helium cannot pass through the membranes in humidity-free conditions, but penetrates easily when exposed to humidity, whereas water vapor passes with no resistance. Dry laminates are vacuum-tight, but immersed in water, they act as molecular sieves, blocking some solutes. A third project produced graphene sheets with subnanoscale (0.40 ± 0.24 nm) pores. The graphene was bombarded with gallium ions, which disrupt carbon bonds. Etching the result with an oxidizing solution produces a hole at each spot struck by a gallium ion. The length of time spent in the oxidizing solution determined the average pore size. Pore density reached 5 trillion pores per square centimeter, while retaining structural integrity.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.